Doximity Inc (DOCS)vsNovartis AG ADR (NVS)
DOCS
Doximity Inc
$25.58
+3.52%
HEALTHCARE · Cap: $4.35B
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 8548% more annual revenue ($56.69B vs $655.57M). DOCS leads profitability with a 25.5% profit margin vs 22.5%. DOCS appears more attractively valued with a PEG of 0.59. DOCS earns a higher WallStSmart Score of 59/100 (C).
DOCS
Buy59
out of 100
Grade: C
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.3%
Fair Value
$52.21
Current Price
$25.58
$26.63 discount
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 21 in profit
Keeps 26 of every $100 in revenue as profit
Growing faster than its price suggests
Strong operational efficiency at 21.5%
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Moderate valuation
Weak financial health signals
Earnings declined 51.9%
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : DOCS
The strongest argument for DOCS centers on Debt/Equity, Altman Z-Score, Return on Equity. Profitability is solid with margins at 25.5% and operating margin at 21.5%. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : DOCS
The primary concerns for DOCS are P/E Ratio, Piotroski F-Score, EPS Growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
DOCS profiles as a mature stock while NVS is a value play — different risk/reward profiles.
DOCS carries more volatility with a beta of 1.25 — expect wider price swings.
DOCS is growing revenue faster at 7.3% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
DOCS scores higher overall (59/100 vs 51/100), backed by strong 25.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Doximity Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Doximity, Inc. (Ticker: DOCS) is a U.S. healthcare technology company that operates a digital platform tailored for medical professionals. The company’s cloud-based network provides secure communication and collaboration tools, telemedicine services, clinical workflow solutions, and access to medical news, research, and career-management features for physicians, nurse practitioners, physician assistants, and other clinicians. Headquartered in San Francisco, California, Doximity’s Class A common stock trades on the New York Stock Exchange under the ticker DOCS.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?